Congenital Abnormalities  >>  Lucentis (ranibizumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lucentis (ranibizumab) / Roche, Novartis
NCT00510965 / 2006-006231-49: Ranibizumab to Treat Choroidal Neovascularization (CNV) in Patients With Pseudoxanthoma Elasticum (PXE)

Completed
2
10
Europe
Intravitreal injection ranibizumab, Lucentis
University Hospital, Bonn, Novartis
Choroidal Neovascularization
04/10
04/10

Download Options